Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 111 publications
Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: February 18, 2026
Characterizing therapeutic target antigen expression in anaplastic carcinoma of the ovary.
Journal: Gynecologic oncology reports
Published: February 06, 2026
Management of low-grade serous carcinoma of the ovary.
Journal: Clinical advances in hematology & oncology : H&O
Published: December 29, 2025
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.
Journal: Future oncology (London, England)
Published: December 12, 2025
A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 26, 2025
Mitogen-Activated Protein Kinase Driven Rare Gynecologic Cancers and Evolving Therapeutic Targets.
Journal: Hematology/oncology clinics of North America
Published: October 31, 2025
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2025
A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer.
Journal: Gynecologic oncology
Published: August 01, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 23, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 11, 2025
Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours.
Journal: Clinical and translational medicine
Published: April 04, 2025
Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics.
Journal: Gynecologic oncology
Published: March 12, 2025
Last Updated: 09/26/2026